Health Catalyst, Inc. (NASDAQ:HCAT) Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. raised its stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 17.8% during the second quarter, HoldingsChannel reports. The firm owned 3,502,231 shares of the company’s stock after purchasing an additional 530,293 shares during the quarter. Vanguard Group Inc. owned approximately 0.08% of Health Catalyst worth $194,409,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the business. BlackRock Inc. increased its stake in shares of Health Catalyst by 78.8% in the second quarter. BlackRock Inc. now owns 4,519,656 shares of the company’s stock worth $250,888,000 after acquiring an additional 1,991,894 shares during the period. Alliancebernstein L.P. increased its stake in shares of Health Catalyst by 7.5% in the second quarter. Alliancebernstein L.P. now owns 2,124,875 shares of the company’s stock worth $117,952,000 after acquiring an additional 147,927 shares during the period. Janus Henderson Group PLC increased its stake in shares of Health Catalyst by 0.7% in the first quarter. Janus Henderson Group PLC now owns 1,447,832 shares of the company’s stock worth $67,715,000 after acquiring an additional 10,138 shares during the period. First Light Asset Management LLC increased its stake in shares of Health Catalyst by 2.6% in the first quarter. First Light Asset Management LLC now owns 997,201 shares of the company’s stock worth $46,639,000 after acquiring an additional 25,304 shares during the period. Finally, Victory Capital Management Inc. increased its stake in shares of Health Catalyst by 4.5% in the second quarter. Victory Capital Management Inc. now owns 877,638 shares of the company’s stock worth $48,717,000 after acquiring an additional 37,604 shares during the period.

In related news, CAO Jason Alger sold 652 shares of the firm’s stock in a transaction dated Friday, September 3rd. The shares were sold at an average price of $54.23, for a total transaction of $35,357.96. Following the completion of the sale, the chief accounting officer now directly owns 15,312 shares in the company, valued at $830,369.76. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Paul Horstmeier sold 10,750 shares of the firm’s stock in a transaction dated Tuesday, October 5th. The stock was sold at an average price of $48.09, for a total transaction of $516,967.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 150,076 shares of company stock worth $8,100,587. Insiders own 2.00% of the company’s stock.

HCAT has been the topic of a number of research reports. Citigroup increased their price objective on shares of Health Catalyst from $62.00 to $68.00 and gave the stock a “buy” rating in a research note on Monday, August 9th. Piper Sandler raised their price target on shares of Health Catalyst from $57.00 to $66.00 and gave the company an “overweight” rating in a research report on Friday, August 6th. Zacks Investment Research lowered shares of Health Catalyst from a “buy” rating to a “hold” rating in a research report on Monday. Raymond James raised their price target on shares of Health Catalyst from $66.00 to $70.00 and gave the company a “strong-buy” rating in a research report on Tuesday, August 10th. Finally, Canaccord Genuity raised their price target on shares of Health Catalyst from $60.00 to $64.00 and gave the company a “buy” rating in a research report on Friday, August 6th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Health Catalyst presently has an average rating of “Buy” and a consensus target price of $60.37.

HCAT opened at $49.86 on Thursday. The company has a market cap of $2.32 billion, a price-to-earnings ratio of -15.88 and a beta of 0.69. Health Catalyst, Inc. has a 52-week low of $32.63 and a 52-week high of $59.50. The firm’s fifty day simple moving average is $51.77 and its two-hundred day simple moving average is $53.46.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Thursday, August 5th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.02. The business had revenue of $59.63 million for the quarter, compared to the consensus estimate of $56.68 million. Health Catalyst had a negative net margin of 62.31% and a negative return on equity of 24.68%. As a group, sell-side analysts expect that Health Catalyst, Inc. will post -1.83 earnings per share for the current fiscal year.

Health Catalyst Profile

Health Catalyst, Inc engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers.

Featured Story: What is the S&P 500 Index?

Want to see what other hedge funds are holding HCAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Health Catalyst, Inc. (NASDAQ:HCAT).

Institutional Ownership by Quarter for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.